Soleus Private Equity Fund III L.P. 13D and 13G filings for Mereo BioPharma Group plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 3:30 pm Sale |
2024-09-30 | 13G | Mereo BioPharma Group plc MREO |
Soleus Private Equity Fund III L.P. | 4,234,765 0.500% |
-44,652,330 (-91.34%) |
Filing |
| 2024-02-06 4:15 pm Purchase |
2023-12-31 | 13G | Mereo BioPharma Group plc MREO |
Soleus Private Equity Fund III L.P. | 48,887,095 7.000% |
500,000 (+1.03%) |
Filing |
| 2023-07-26 4:31 pm Purchase |
2023-07-24 | 13G | Mereo BioPharma Group plc MREO |
Soleus Private Equity Fund III L.P. | 48,387,095 7.500% |
48,387,095 (New Position) |
Filing |